1 unchanged sentence
Market Information
−Removed: Since the completion of our Merger with NantCell, Inc.
−Removed: (formerly known as ImmunityBio, Inc.) on March 9, 2021, our common stock has been traded under the ticker symbol “IBRX” on the Nasdaq Global Select Market.
−Removed: Prior to the Merger, our common stock was traded under the ticker symbol “NK” on the Nasdaq Global Select Market from July 28, 2015 through March 8, 2021, the day before the consummation of the Merger.
+Added: Our common stock is traded under the ticker symbol “IBRX” on the Nasdaq Global Select Market.
Holders of Record
6 unchanged sentences
Securities Authorized for Issuance Under Equity Compensation Plans
−Removed: The following table sets forth information regarding our equity compensation plans in effect as of December 31, 2021 (including upon the exercise of stock options and the vesting restricted stock units (RSUs):
+Added: The following table sets forth information regarding our equity compensation plans in effect as of December 31, 2022 (including upon the exercise of stock options and the vesting of restricted stock units (RSUs)):
Equity Compensation Plan Information
20 unchanged sentences
(3) The amount shown in Column (b) is the weighted average exercise price for stock options outstanding.
−Removed: (4) The amount shown in Column (c) is the number of shares available for grant under the 2015 Plan.
+Added: (4) The amount shown in Column (c) is the number of shares available for future grants under the 2015 Plan.
Stock Performance Graph
2 unchanged sentences
The returns shown are based on historical results and are not indicative of, or intended to forecast, future performance of our common stock or the comparative indices.
−Removed: This performance graph shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference into any filing of ImmunityBio, Inc.
−Removed: under the Securities Act of 1933, as amended (the Securities Act).
+Added: This performance graph shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference into any filing of ImmunityBio, Inc.
+Added: under the Securities Act.
COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*
3 unchanged sentences
Issuer Purchases of Equity Securities
−Removed: We did not repurchase any shares of our common stock during the three months ended December 31, 2021.
−Removed: As of December 31, 2021, $18.3 million remained authorized for repurchase under our stock repurchase program.
−Removed: For additional information regarding our stock repurchase program, see Note 9 , Stockholders’ Deficit, of the “Notes to Consolidated Financial Statements” that appears in Part II, Item 8.
+Added: No shares of our common stock were repurchased during the three months ended December 31, 2022 under the 2015 Share Repurchase Program.
+Added: As of December 31, 2022, $18.3 million remained authorized to use for share repurchases under the program.
+Added: For additional information regarding the 2015 Share Repurchase Program, see Note 12 , Stockholders’ Deficit, of the “Notes to Consolidated Financial Statements” that appears in Part II, Item 8.
“Financial Statements and Supplementary Data” of this Annual Report.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.